KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Equity Ratio: 2018-2025

Historic Equity Ratio for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to 0.83.

  • Castle Biosciences' Equity Ratio fell 3.18% to 0.83 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.83, marking a year-over-year decrease of 3.18%. This contributed to the annual value of 0.86 for FY2024, which is 0.58% down from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Equity Ratio is 0.83, which was down 0.73% from 0.84 recorded in Q2 2025.
  • Castle Biosciences' 5-year Equity Ratio high stood at 0.96 for Q1 2021, and its period low was 0.83 during Q3 2025.
  • Moreover, its 3-year median value for Equity Ratio was 0.87 (2024), whereas its average is 0.87.
  • In the last 5 years, Castle Biosciences' Equity Ratio skyrocketed by 30.90% in 2021 and then declined by 6.59% in 2022.
  • Castle Biosciences' Equity Ratio (Quarterly) stood at 0.89 in 2021, then increased by 0.25% to 0.89 in 2022, then decreased by 3.27% to 0.86 in 2023, then declined by 0.58% to 0.86 in 2024, then decreased by 3.18% to 0.83 in 2025.
  • Its Equity Ratio stands at 0.83 for Q3 2025, versus 0.84 for Q2 2025 and 0.88 for Q1 2025.